The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Eylea, developed by Regeneron Pharmaceuticals Inc. (REGN), is approved in the U.S. for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following ...

Ocular Therapeutix (NASDAQ:OCUL) traded higher in the morning hours on Tuesday after Needham initiated its coverage with a Buy rating and a $15 per share target, citing the potential of its lead ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...

Despite falling Eylea sales, Regeneron Pharmaceuticals once again beats Wall Street expectations Regeneron's revenue was about $3.79 billion in the fourth quarter of 2024, up 10.5% year-on-year ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...